
## Michiel J Thomeer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/299928/publications.pdf Version: 2024-02-01



MICHIEL THOMEER

#	Article	IF	CITATIONS
1	Passage of Inhaled Particles Into the Blood Circulation in Humans. Circulation, 2002, 105, 411-414.	1.6	1,380
2	High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2005, 353, 2229-2242.	13.9	880
3	Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet, The, 2009, 374, 222-228.	6.3	464
4	Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1382-1389.	2.5	390
5	Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1231-1237.	2.5	369
6	Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 459-466.	2.5	367
7	Treatment of Idiopathic Pulmonary Fibrosis with Etanercept. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 948-955.	2.5	338
8	Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. European Respiratory Journal, 2008, 31, 1189-1196.	3.1	271
9	Methotrexate vs Azathioprine in Second-line Therapy of Sarcoidosis. Chest, 2013, 144, 805-812.	0.4	210
10	Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2008, 31, 585-591.	3.1	138
11	Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax, 2005, 60, 32-38.	2.7	124
12	REGISTRATION OF INTERSTITIAL LUNG DISEASES BY 20 CENTRES OF RESPIRATORY MEDICINE IN FLANDERS. Acta Clinica Belgica, 2001, 56, 163-172.	0.5	118
13	The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism. Frontiers in Oncology, 2019, 9, 1215.	1.3	97
14	Glutamine Addiction and Therapeutic Strategies in Lung Cancer. International Journal of Molecular Sciences, 2019, 20, 252.	1.8	82
15	Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Annals of Oncology, 2013, 24, 986-992.	0.6	76
16	Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax, 2012, 67, 938-940.	2.7	71
17	Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial. Respiratory Research, 2009, 10, 101.	1.4	70
18	Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model. Experimental Lung Research, 2010, 36, 602-614.	0.5	57

MICHIEL J THOMEER

#	Article	IF	CITATIONS
19	Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment. Respiratory Medicine, 2004, 98, 567-573.	1.3	55
20	Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma. Journal of Thoracic Oncology, 2016, 11, 516-523.	0.5	54
21	Medical thoracoscopic lung biopsy in interstitial lung disease: a prospective study of biopsy quality. European Respiratory Journal, 1999, 14, 585.	3.1	51
22	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1458-1467.	0.5	50
23	Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?. European Respiratory Journal, 2020, 56, 2001201.	3.1	50
24	Are Randomized Controlled Trials the (G)old Standard? From Clinical Intelligence to Prescriptive Analytics. Journal of Medical Internet Research, 2016, 18, e185.	2.1	39
25	Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Lung Cancer, 2018, 115, 49-55.	0.9	38
26	An Algorithm to Tackle Acute Exacerbations in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1397-1397.	2.5	33
27	Clinical use of biomarkers of survival in pulmonary fibrosis. Respiratory Research, 2010, 11, 89.	1.4	28
28	Phenotyping human blood plasma by 1H-NMR: a robust protocol based on metabolite spiking and its evaluation in breast cancer. Metabolomics, 2015, 11, 225-236.	1.4	28
29	Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS. Neurology, 2003, 61, 1150-1151.	1.5	27
30	Influence of preanalytical sampling conditions on the 1H NMR metabolic profile of human blood plasma and introduction of the Standard PREanalytical Code used in biobanking. Metabolomics, 2015, 11, 1197-1207.	1.4	27
31	Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). Journal of Thoracic Oncology, 2016, 11, 85-93.	O.5	26
32	Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types?. Annals of Oncology, 2016, 27, 178-184.	0.6	24
33	Hypogonadism in male outpatients with sarcoidosis. Respiratory Medicine, 2007, 101, 2502-2510.	1.3	23
34	Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. Cancer Treatment and Research Communications, 2018, 15, 7-12.	0.7	19
35	A RANDOMIZED PLACEBO CONTROLLED TRIAL ASSESSING THE EFFICACY AND SAFETY OF ETANERCEPT IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF). Chest, 2005, 128, 496S.	0.4	15
36	Plausibility and redundancy analysis to select FDGâ€PET textural features in nonâ€small cell lung cancer. Medical Physics, 2021, 48, 1226-1238.	1.6	15

MICHIEL J THOMEER

#	Article	IF	CITATIONS
37	Repeatability of two semi-automatic artificial intelligence approaches for tumor segmentation in PET. EJNMMI Research, 2021, 11, 4.	1.1	15
38	Systemic lupus erythematosus, eosinophilia and Löffler′s endocarditis. An unusual association. European Respiratory Journal, 1999, 13, 930.	3.1	14
39	Metabolic phenotyping of human plasma by <sup>1</sup> Hâ€NMR at high and medium magnetic field strengths: a case study for lung cancer. Magnetic Resonance in Chemistry, 2017, 55, 706-713.	1.1	13
40	The plasma glutamate concentration as a complementary tool to differentiate benign PET-positive lung lesions from lung cancer. BMC Cancer, 2018, 18, 868.	1.1	13
41	Impact of acute exacerbations of COPD on patients' health status beyond pulmonary function: A scoping review. Pulmonology, 2023, 29, 518-534.	1.0	11
42	Remote patient monitoring in COVID-19: a critical appraisal. European Respiratory Journal, 2022, 59, 2102697.	3.1	9
43	A New Missense Mutation in theCASRGene in Familial Interstitial Lung Disease with Hypocalciuric Hypercalcemia and Defective Granulocyte Function. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 558-559.	2.5	8
44	2015, big data in healthcare: for whom the bell tolls?. Critical Care, 2015, 19, 171.	2.5	8
45	A breathless accountant who blew up balloons. Lancet, The, 1999, 354, 124.	6.3	7
46	Pertechnegas lung clearance in different forms of interstitial lung disease. European Respiratory Journal, 2002, 19, 31-36.	3.1	7
47	Correlations between the metabolic profile and 18F-FDG-Positron Emission Tomography-Computed Tomography parameters reveal the complexity of the metabolic reprogramming within lung cancer patients. Scientific Reports, 2019, 9, 16212.	1.6	7
48	Sarcoidosis around the Globe. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 393-403.	0.8	6
49	Detection of Lung Cancer via Blood Plasma and 1H-NMR Metabolomics: Validation by a Semi-Targeted and Quantitative Approach Using a Protein-Binding Competitor. Metabolites, 2021, 11, 537.	1.3	6
50	Disseminated Mycobacterium tilburgii infection in a non-HIV-infected patient. Clinical Microbiology Newsletter, 2007, 29, 62-64.	0.4	5
51	Newer modes of treating interstitial lung disease. Current Opinion in Pulmonary Medicine, 2011, 17, 332-336.	1.2	5
52	Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT Journal of Clinical Oncology, 2011, 29, 7002-7002.	0.8	5
53	Changes in Metabolism as a Diagnostic Tool for Lung Cancer: Systematic Review. Metabolites, 2022, 12, 545.	1.3	4
54	MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy Journal of Clinical Oncology, 2012, 30, 7013-7013.	0.8	3

MICHIEL J THOMEER

#	Article	IF	CITATIONS
55	Unraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics. International Journal of Molecular Sciences, 2022, 23, 5602.	1.8	3
56	External validity of randomised controlled trials in idiopathic pulmonary fibrosis. European Respiratory Journal, 2006, 27, 1072.1-1072.	3.1	2
57	CATEGORICAL DECLINES IN PERCENT PREDICTED FORCED VITAL CAPACITY (PP-FVC) ARE ASSOCIATED WITH A GRADED RISK OF DEATH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF). Chest, 2008, 134, 20S.	0.4	2
58	6-Minute Walk Test Distance (6MWD) Is A Reliable, Valid, And Responsive Outcome Measure That Predicts Mortality In Patients With IPF. , 2010, , .		2
59	Metabolomics a Novel Biomarker in Lung Cancer. Journal of Thoracic Oncology, 2015, 10, e46.	0.5	2
60	New Idiopathic Pulmonary Fibrosis Guidelines: Some Unresolved Questions. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 588-588.	2.5	1
61	Validation of 1H-Nmr-Based Metabolomics As a Tool to Detect Lung Cancer in Human Blood Plasma. Annals of Oncology, 2014, 25, iv406.	0.6	1
62	Classification and new developments in the pathogenesis of vasculitis. , 2005, , 50-68.		1
63	Diffuse interstitiële longaandoeningen: actuele inzichten in diagnostiek en ziekteopvolging. Tijdschrift Voor Geneeskunde, 2001, 57, 953-962.	0.0	1
64	Treatment strategies for sarcoidosis. Acta Clinica Belgica, 2012, 67, 83-7.	0.5	1
65	New Idiopathic Pulmonary Fibrosis Guidelines: Some Unresolved Questions. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 588-589.	2.5	0
66	Diagnosis of Lung Cancer: What Metabolomics Can Contribute. , 2018, , .		0
67	Fever and an abnormal chest X-ray during the COVID-19 pandemic. Respiratory Medicine Case Reports, 2020, 31, 101167.	0.2	Ο
68	Clinical manifestation, approach to diagnosis and treatment of pulmonary vasculitis. , 2005, , 69-90.		0
69	SarcoÃ⁻dose: een adembenemende aandoening. Tijdschrift Voor Geneeskunde, 2007, 63, 987-994.	0.0	0